The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 24, 2015

Filed:

Aug. 20, 2008
Applicants:

Susan Zolla-pazner, New York, NY (US);

Miroslaw K. Gorny, Harrison, NY (US);

Timothy J. Cardozo, New York, NY (US);

Xiang-peng Kong, New York, NY (US);

Ruben Abagyan, La Jolla, CA (US);

Maxim Totrov, San Diedo, CA (US);

Shan LU, Franklin, MA (US);

Abraham Pinter, Brooklyn, NY (US);

Inventors:

Susan Zolla-Pazner, New York, NY (US);

Miroslaw K. Gorny, Harrison, NY (US);

Timothy J. Cardozo, New York, NY (US);

Xiang-peng Kong, New York, NY (US);

Ruben Abagyan, La Jolla, CA (US);

Maxim Totrov, San Diedo, CA (US);

Shan Lu, Franklin, MA (US);

Abraham Pinter, Brooklyn, NY (US);

Assignees:

New York University, New York, NY (US);

Molsoft LLC, La Jolla, CA (US);

University of Massachusetts, Boston, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/21 (2006.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01); C07K 14/005 (2006.01); A61K 38/03 (2006.01); A61K 38/16 (2006.01);
U.S. Cl.
CPC ...
C07K 14/005 (2013.01); A61K 38/03 (2013.01); A61K 38/16 (2013.01); A61K 39/00 (2013.01); A61K 39/21 (2013.01); C07K 2319/35 (2013.01); C07K 2319/55 (2013.01); C12N 2740/16122 (2013.01); C12N 2740/16134 (2013.01);
Abstract

Insertion of HIV-1 V3 loop peptides from the viral glycoprotein gp120 into selected, immunogenic scaffold proteins results in a recombinant polypeptide that is a potent V3 immunogen. V3 immunogens include natural and consensus V3 sequences and cyclic and reverse peptides. Preferred scaffold proteins are Cholera Toxin subunit B and homologues thereof including closely relatedenterotoxins. Such immunogenic polypeptides induce broadly reactive anti-gp120 antibodies specific for V3 epitopes that can neutralize heterologous HIV-1 subtypes and strains. These polypeptide, methods for preparing them, and methods for inducing anti-gp120 (V3-specific) antibody) responses using them are disclosed.


Find Patent Forward Citations

Loading…